

Medical Policy:

RITUXIMAB Injectable (Riabni[®], Rituxan[®], Ruxience[®], Truxima[®]) Intravenous

POLICY NUMBER	LAST REVIEW	ORIGIN DATE
MG.MM.PH.102	August 18, 2023	

Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved.

The treating physician or primary care provider must submit to EmblemHealth, or ConnectiCare, as applicable (hereinafter jointly referred to as “EmblemHealth”), the clinical evidence that the member meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request preauthorization or post-payment review. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. This clinical policy is not intended to pre-empt the judgment of the reviewing medical director or dictate to health care providers how to practice medicine. Health care providers are expected to exercise their medical judgment in rendering appropriate care. Health care providers are expected to exercise their medical judgment in rendering appropriate care.

EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary.

If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. Identification of selected brand names of devices, tests and procedures in a medical coverage policy is for reference only and is not an endorsement of any one device, test or procedure over another. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication.

EmblemHealth may also use tools developed by third parties, such as the MCG[™] Care Guidelines, to assist us in administering health benefits. The MCG[™] Care Guidelines are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice. EmblemHealth Services Company, LLC, has adopted this policy in providing management, administrative and other services to EmblemHealth Plan, Inc., EmblemHealth Insurance Company, EmblemHealth Services Company, LLC, and Health Insurance Plan of Greater New York (HIP) related to health benefit plans offered by these entities. ConnectiCare, an EmblemHealth company, has also adopted this policy. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Length of Authorization

Coverage will be provided for 6 months (12 months initially for pemphigus vulgaris) and may be renewed unless otherwise specified.

- Maintenance therapy for oncology indications (excluding ALL) may be renewed for up to a maximum of 2 years.
- Adult Acute Lymphoblastic Leukemia (ALL) may be renewed for a maximum of 18 doses.
- Mantle Cell Lymphoma may be renewed until disease progression or intolerable toxicity.
- Hairy Cell Leukemia may NOT be renewed.
- Induction/Consolidation of Pediatric B-Cell Acute Leukemia and Aggressive Mature B-Cell Lymphomas may NOT be renewed.
- Pediatric Hodgkin Lymphoma may NOT be renewed.

- Management of Immunotherapy-Related Toxicities:
 - Myositis/Myasthenia Gravis/Encephalitis may NOT be renewed.
 - Bullous Dermatitis may be renewed for a maximum of 18 months (4 total doses).
- Chronic Graft-Versus-Host Disease (cGVHD) may NOT be renewed.
- Hematopoietic Cell Transplantation may NOT be renewed.
- Lupus Nephritis may be renewed ONLY in patients experiencing a disease relapse.
- Complications of Transplanted Solid Organ may NOT be renewed.
- Relapse therapy for pemphigus vulgaris must be at least 16 weeks past a prior infusion

Dosing Limits [Medical Benefit]

A. Max Units (per dose and over time):

Oncology Indications
Chronic Lymphocytic Leukemia (CLL): <ul style="list-style-type: none"> • Initial therapy: <ul style="list-style-type: none"> ○ Loading dose: 100 billable units x 1 dose ○ Subsequent doses: 130 billable units x 5 doses per 6 months • Renewal therapy: 130 billable units every 8 weeks
Immunotherapy Toxicity Treatment: <ul style="list-style-type: none"> • 375mg/m² dose weekly x 4 doses in a 6-month period
All other oncology indications: <ul style="list-style-type: none"> • Initial therapy: 100 billable units weekly x 8 doses per 6 months • Renewal therapy: 100 billable units x 4 doses per 6 months
Non-Oncology Indications
Rheumatoid Arthritis (RA): <ul style="list-style-type: none"> • 100 billable units every 14 days x 2 doses in a 16 week period
Pemphigus Vulgaris: <ul style="list-style-type: none"> • Initiation: 100 billable units weekly x 4 doses in a 12 month period • Maintenance: 50 billable units every 16 weeks
cGVHD <ul style="list-style-type: none"> • 100 billable units weekly x 8 doses
All other non-oncology indications: <ul style="list-style-type: none"> • 100 billable units weekly x 4 doses in a 6 month period

Guideline

I. Initial Approval Criteria

For Commercial, Medicaid, and Medicare members:

1. Non-preferred agent: Rituxan and Riabni
2. Preferred agents: Ruxience and Truxima

Coverage is provided in the following conditions (in addition to use supported by the National Comprehensive Cancer Network [NCCN] Clinical Practice Guidelines [NCCN Guidelines®] and/or NCCN Drugs & Biologics Compendium [NCCN Compendium®] with a recommendation of category level 1 or 2A*):

1. Patient must be screened for HBV infection (i.e., HBsAg and anti-HBc) prior to initiating therapy; **AND**
2. For newly started Rituxan or Riabni therapy, for Commercial, Medicaid, and Medicare members:

Coverage may be considered medically necessary when:

- a. Patient has experienced a therapeutic failure or intolerance with the plan-preferred medications (Ruxience AND Truxima); **OR**
- b. Rituxan or Riabni is requested for an indication for which the plan-preferred biosimilar agents (Ruxience or Truxima) have not been FDA-approved OR are not supported by NCCN Guidelines® or NCCN Compendium® with a recommendation of category level 1 or 2A; **AND**

**Please note: Coverage for an appropriate biosimilar substitution will be allowed where NCCN Guidelines or Compendium state that an FDA-approved biosimilar is an appropriate substitution for rituximab.*

Oncology Indications:

Patient is CD20-positive; **AND**

Pediatric Mature B-Cell Acute Leukemia †

1. Patient is at least 6 months of age; **AND**
2. Used in combination with chemotherapy for previously untreated disease

Acute Lymphoblastic Leukemia (ALL) ‡

1. Induction/Consolidation Treatment
 - a. Patient's disease is Philadelphia chromosome-negative (Ph-); **AND**
 - i. Patient is at least 15 years of age; **AND**
 - Used in combination with an anthracycline, cyclophosphamide and vincristine-based regimen
2. Relapsed/Refractory Treatment
 - a. Used as a component of MOpAD regimen (methotrexate, vincristine, pegaspargase, dexamethasone); **AND**
 - i. Patient's disease is Philadelphia chromosome-negative (Ph-); **OR**

CNS Cancer ‡

1. Patient has leptomeningeal metastases from lymphomas; **AND**
2. Patient has primary CNS lymphoma; **AND**
 - a. Used for induction therapy; **AND**
 - b. Used as a single agent OR in combination with a methotrexate-containing regimen, temozolomide, or lenalidomide; **OR**
 - c. Patient has CSF positive or spinal MRI positive disease; **OR**
 - ii. Used for consolidation (monthly maintenance) therapy; **AND**

- a. Used as continuation of induction regimen in patients with complete response or complete response unconfirmed (CRu) to induction therapy; **AND**
 - 1.)Used as a single agent§; **OR**
 - 2.)Used on combination with high-dose methotrexate¥; **OR**
- iii. Used for relapsed or refractory disease; **AND**
 - a. Used as a single agent OR in combination with systemic therapy in patients with prior whole brain radiation therapy§; **AND**
 - 1.)Patient has CSF positive or spinal MRI positive disease; OR
 - b. Used as a single agent OR in combination with temozolomide, lenalidomide, or highdose methotrexate¥

§ For intrathecal administration ONLY; ¥ For intravenous administration ONLY

Hodgkin’s lymphoma ‡

- 1. Patient has nodular lymphocyte-predominant disease

Chronic lymphocytic leukemia/Small lymphocytic lymphoma (CLL/SLL) †

Waldenström’s macroglobulinemia/Lymphoplasmacytic Lymphoma ‡

Non-Hodgkin’s lymphomas (NHL) † including, but not limited to, the following:

- 1. AIDS-related B-Cell Lymphoma ‡
- 2. Burkitt Lymphoma ‡
- 3. Castleman’s Disease ‡
- 4. Diffuse Large B-Cell Lymphoma †
- 5. Low-grade or Follicular Lymphoma †
- 6. Extranodal Marginal Zone Lymphoma (EMZL) of the Stomach & Nongastric Sites (Noncutaneous) ‡
- 7. High-Grade B-Cell Lymphomas ‡
- 8. Mantle Cell Lymphoma ‡
- 9. Nodal & Splenic Marginal Zone Lymphoma ‡
- 10. Post-transplant lymphoproliferative disorder (PTLD) ‡

Management of Immunotherapy-Related Toxicities ‡

- 1. Patient has been receiving therapy with an immune checkpoint inhibitor (e.g. cemiplimab ,nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, ipilimumab, dostarlimab,
- 2. nivolumab/relatlimab-rmbw etc.); **AND**
- 3. Patient has encephalitis related to their immunotherapy; **AND**
- 4. Patient is autoimmune-encephalopathy-antibody positive; **AND**
- 5. Patient has had limited to no improvement after 7 to 14 days on pulse-dose corticosteroids with or without intravenous immunoglobulin (IVIG); **OR**

6. Patient has bullous dermatitis related to immunotherapy; **AND**
 - a. Used as additional therapy for moderate (G2), severe (G3) or life-threatening (G4) disease; **OR**
7. Patient has moderate, severe, or life-threatening steroid-refractory myositis (proximal muscle weakness, neck flexor weakness, with or without myalgias) related to immunotherapy; **AND**
 - a. Used for significant dysphagia, life-threatening situations, or cases refractory to corticosteroids; **OR**
8. Patient has myasthenia gravis related to immunotherapy; **AND**
 - a. Used as additional therapy for severe (G3-4) disease that is refractory to plasmapheresis or IVIG

Non-Oncology Indications:

Rheumatoid arthritis (RA) †

- | |
|---|
| 1. Medication must be requested by a Rheumatologist; AND |
|---|
2. Adult patient (18 years or older); **AND**
 3. Documented moderate to severe disease; **AND**
 4. Must be used in combination with methotrexate unless the patient has a contraindication or intolerance; **AND**
 5. Patient tried and failed at least a 3-month trial with ONE oral disease modifying anti-rheumatic drug (DMARD) (e.g., methotrexate, azathioprine, auranofin, hydroxychloroquine, penicillamine, sulfasalazine, leflunomide, etc.); **AND**
 6. Previous failure with one or more preferred TNF antagonists at least one of which should be a self-injectable; **AND**
 7. Physician has assessed baseline disease severity utilizing an objective measure/tool; **AND**
 8. Patient has not had treatment with Rituxan, Riabni, Ruxience, or Truxima in the previous 4 months

Pemphigus vulgaris †

1. Adult patient (18 years or older); **AND**
2. Patient has a diagnosis of pemphigus vulgaris as determined by one or more of the following:
 - a. Clinical features
 - i. Appearance of lesions, erosions and/or blisters
 - ii. Nikolsky sign (induction of blistering via mechanical pressure at the edge of a blister or on normal skin)
 - iii. Characteristic scarring and lesion distribution; **AND**
 - b. Histopathologic confirmation by skin/mucous membrane biopsy; **AND**
 - c. Positive direct immunofluorescence (DIF) microscopy result **OR** Presence of autoantibodies as detected by direct immunofluorescence or enzyme-linked immunosorbent assay (ELISA); **AND**
3. Patient has moderate to severe disease as assessed utilizing an objective measure/tool (i.e. PDAI, PSS, ABSIS); **AND**
4. Patient is on combination glucocorticoid therapy; **AND**

5. Other causes of blistering or erosive skin and mucous membrane diseases have been ruled out

Granulomatosis with Polyangiitis (GPA) (Wegener's granulomatosis) and Microscopic Polyangiitis (MPA) †

1. Adult and pediatric patients (2 years or older); **AND**
2. Used in combination with glucocorticoids

Thrombocytopenic purpura ‡

1. Patient diagnosis includes one of the following:
 - a. Primary thrombocytopenia
 - b. Idiopathic (Immune) thrombocytopenia purpura (ITP)
 - c. Evan's syndrome; **AND**
2. Patient has previously failed or has a contraindication or intolerance to therapy with corticosteroids; **AND**
3. Patient is at increased risk for bleeding as indicated by platelet count (within the previous 28 days) less than $30 \times 10^9/L$ (30,000/mm³)

Chronic graft-versus-host disease (cGVHD) ‡

1. Patient is post-allogeneic stem cell transplant (generally 3 or more months); **AND**
2. Used as additional therapy in combination with corticosteroids; **AND**
3. Patient has no response (e.g., steroid-refractory disease) to first-line therapy options; **AND**
4. Patient must try and have an inadequate response, contraindication, or intolerance to at least a three (3) month trial of ibrutinib.

Autoimmune Hemolytic Anemia (AIHA) ‡

1. Patient has warm-reactive disease refractory to or dependent on glucocorticoids; **OR**
2. Patient has cold agglutinin disease with symptomatic anemia, transfusion-dependence, and/or disabling circulatory symptoms

† FDA-labeled indication(s); ‡ Compendia recommended indication(s)

II. Renewal Criteria

Coverage can be renewed based upon the following criteria:

1. Continuation of documented current and/or successful therapy with a non-preferred agent (Rituxan or Riabni); **AND**
2. Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include the following: severe infusion reactions, tumor lysis syndrome (TLS), severe mucocutaneous reactions, progressive multifocal leukoencephalopathy (PML), viral hepatitis, serious bacterial, fungal, or viral infections, cardiac arrhythmias, renal toxicity, bowel obstruction or perforation; **AND**

Oncology Indications:

1. Tumor response with stabilization of disease or decrease in size of tumor or tumor spread; **AND**
2. Patient has not exceeded dosing or duration limits as defined above

Non-Oncology Indications:

Rheumatoid arthritis (RA)

1. Disease response as indicated by improvement in signs and symptoms compared to baseline such as the number of tender and swollen joint counts and/or an improvement on a disease activity scoring tool [e.g. an improvement on a composite scoring index such as Disease Activity Score-28 (DAS28) of 1.2 points or more or a $\geq 20\%$ improvement on the American College of Rheumatology-20 (ACR20) criteria]; **AND**
2. Dose escalation (up to the maximum dose and frequency specified below) may occur upon clinical review on a case-by-case basis provided that the patient has:
 - a. Shown an initial response to therapy; **AND**
 - b. Received a minimum of one maintenance dose at the dose and interval specified below; **AND**
 - c. Responded to therapy with subsequent loss of response

Thrombocytopenic purpura

1. Disease response as indicated by the achievement and maintenance of a platelet count of at least $50 \times 10^9/L$ as necessary to reduce the risk for bleeding

Granulomatosis with Polyangiitis (GPA) (Wegener's granulomatosis) and Microscopic polyangiitis (MPA)

1. Disease response as indicated by improvement in signs and symptoms of condition compared to baseline; **AND**
2. Decreased frequency in the occurrence of major relapses (defined by the reappearance of clinical and/or laboratory signs of vasculitis activity that could lead to organ failure or damage, or could be life threatening)

Pemphigus vulgaris

1. Patient is currently receiving tapering doses of corticosteroids or has discontinued use of corticosteroids; **AND**
 - a. Disease response as indicated by complete epithelialization of lesions and improvement in signs and symptoms of condition compared to baseline; **OR**
 - b. Patient has not experienced continued development of new lesions, continued extension of old lesions, or failure of established lesions to begin to heal despite therapy; **OR**
 - ii. For Relapses ONLY: Patient has had active disease control; **AND**
 - iii. Patient has the appearance of 3 or more new lesions a month that do not heal spontaneously within 1 week, or by the extension of established lesions

Chronic graft-versus-host disease (cGVHD)

1. Coverage may NOT be renewed

Autoimmune hemolytic anemia (AIHA)

1. Disease response as indicated by improvement in anemia signs and symptoms (e.g., dyspnea, fatigue, etc.) ; **AND**
2. Patient has improvement in laboratory values (Hb/Hct), reduced transfusion needs, and/or reduced glucocorticoid use

Dosage and Administration

[Riabni Prescribing Information](#)

[Rituxan Prescribing Information](#)

[Ruxience Prescribing Information](#)

[Truxima Prescribing Information](#)

Indication		Dose
CLL	Initial Therapy	375 mg/m ² intravenously (IV) weekly for 8 doses; OR 375 mg/m ² IV cycle 1, then 500 mg/m ² every 28 days cycles 2-6 (6 total doses); OR 375 mg/m ² IV cycle 1, followed by 500 mg/m ² every 2 weeks for 4 doses, then 500 mg/m ² every 28 days for 3 doses (8 total doses)
CLL	Renewal Therapy	375 mg/m ² IV every 3 months; OR 500 mg/ m ² IV every 8 weeks
Adult B-Cell Lymphomas, Primary Cutaneous B-Cell Lymphomas, Waldenström Macroglobulinemia, or Adult HL	Initial Therapy	375 mg/m ² IV once weekly for 4 – 8 doses in a 6 month period
Adult B-Cell Lymphomas, Primary Cutaneous B-Cell Lymphomas, Waldenström Macroglobulinemia, or Adult HL	Renewal Therapy	375 mg/m ² IV once weekly for 4 doses per 6 month period; OR 375 mg/ m ² IV every 8 weeks
ALL		375 mg/m ² IV up to twice weekly for a total of 16 to 18 infusions (e.g., induction [days 1 and 7], salvage reinduction when necessary [days 1 and 7], consolidation [4 infusions: blocks 1, 3, 4, and 6], late intensification [days 1 and 7], late consolidation [2 infusions: blocks 7 and 9], and maintenance [6 infusions])
RA		1,000 mg on days 1 and 15, repeated every 24 weeks. May repeat up to every 16 weeks in patients requiring more frequent dosing based on clinical evaluation.
Pemphigus Vulgaris (PV)		<u>Initiation</u> 1,000 mg IV on days 1 and 15; OR 375 mg/m ² IV weekly for 4 doses <u>Maintenance</u> 500 mg IV at month 12 and repeat every 6 months thereafter or based on clinical evaluation

Indication	Dose
	<p><u>Relapse</u></p> <p>1,000 mg IV upon relapse, resumption of glucocorticoids may be considered</p> <p>*Subsequent infusions (maintenance and relapse) should be no sooner than 16 weeks after the previous infusion.</p>
<p>Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA)</p>	<p><u>Induction (Pediatric and Adult)</u></p> <p>375 mg/m² IV weekly for 4 doses; OR</p> <p>Adults: 1,000 mg IV on days 1 and 15; OR</p> <p>Pediatric (up to a maximum of 1,000 mg per dose):</p> <ul style="list-style-type: none"> o 575 mg/m² IV on days 1 and 15 (BSA ≤1.5m²) o 750 mg/m² IV on days 1 and 15 (BSA >1.5m²) <p><u>Maintenance</u></p> <p>Pediatric:</p> <ul style="list-style-type: none"> o 250 mg/m² IV on days 1 and 15, then 250 mg/m² IV every 6 months thereafter based on clinical evaluation <p>Adult:</p> <ul style="list-style-type: none"> o 500 mg IV on days 1 and 15, then 500 mg IV every 6 months thereafter based on clinical evaluation <p>*Initial MAINTENANCE infusions should be no sooner than 16 weeks and no later than 24 weeks after the previous infusion if rituximab was used for initial induction therapy.</p> <p>*Initial MAINTENANCE infusions should be initiated within 4 weeks following disease control when initial induction occurred with other standard of care immunosuppressants</p>
<p>cGVHD</p>	<p>375 mg/m² IV weekly for 4 doses, then 375 mg/m² IV monthly for 4 months</p> <p>-OR-</p> <p>375 mg/m² IV weekly for 4 doses (Note: A second course of 4 weekly doses may be administered 8 weeks after initial therapy for patients with lack of or incomplete response.)</p> <p>-OR-</p> <p>375 mg/m² IV weekly for 4 – 8 doses</p>

Limitations/Exclusions

Rituxan® (rituximab) is not considered medically necessary for indications other than those listed above due to insufficient evidence of therapeutic value.

Truxima (rituximab-abbs) is indicated for Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA) and Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA). The dosing for the above indications are the same doses as Rituxan.

**Truxima is not indicated for use in ALL, PV, Hodgkin’s lymphoma, ITP, or cGVHD.*

Non-Hodgkin's Lymphoma (NHL)

1. Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent.
2. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy.
3. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.
4. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens.

Chronic Lymphocytic Leukemia (CLL)

1. In combination with fludarabine and cyclophosphamide (FC), for the treatment of adult patients with previously untreated and previously treated CD20-positive CLL.

Rheumatoid Arthritis (RA)

1. In combination with methotrexate, is indicated for the treatment of adult patients with moderately- to severely-active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.

Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA)

1. In combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA)

Ruxience (rituximab-pvvr) is indicated for adults: with Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), RA, Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis), and Microscopic Polyangiitis (MPA). The doses for CLL, GPA/MPA, and NHL are the same doses as Rituxan.

**Ruxience is not indicated for use in ALL, PV, Hodgkin's lymphoma, ITP, or cGVHD.*

Non-Hodgkin's Lymphoma (NHL):

1. Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent.
2. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy.
3. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.
4. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens.

Chronic Lymphocytic Leukemia (CLL)

1. In combination with fludarabine and cyclophosphamide (FC), for the treatment of adult patients with previously untreated and previously treated CD20-positive CLL.

Rheumatoid Arthritis (RA)

1. In combination with methotrexate, is indicated for the treatment of adult patients with moderately- to severely-active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.

Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA)

1. In combination with glucocorticoids, is indicated for the treatment of adult patients with Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA).

Riabni (rituximab-arrx) is indicated for adults: with Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), RA, Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis), and Microscopic Polyangiitis (MPA). The doses for CLL, GPA/MPA, and NHL are the same doses as Rituxan.

**Riabni is not indicated for use in ALL, PV, Hodgkin's lymphoma, ITP, or cGVHD.*

Non-Hodgkin's Lymphoma (NHL):

1. Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent.
2. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy.
3. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.
4. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens.

Rheumatoid Arthritis (RA)

1. In combination with methotrexate, is indicated for the treatment of adult patients with moderately- to severely-active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.

Chronic Lymphocytic Leukemia (CLL)

1. In combination with fludarabine and cyclophosphamide (FC), for the treatment of adult patients with previously untreated and previously treated CD20-positive CLL.

Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA)

1. In combination with glucocorticoids, is indicated for the treatment of adult patients with Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA).

Applicable Procedure Codes

Code	Description
J9312	Injection, rituximab, 10mg
Q5115	Injection, rituximab-abbs, biosimilar, (Truxima), 10 mg

Q5119	Injection, rituximab-pvvr, biosimilar, 10 mg (Ruxience). Effective Date: 07/01/2020
Q5123	Injection, rituximab-arrx, biosimilar, (Riabni), 10 mg

Applicable NDCs

Code	Description
50242-0051-xx	Rituxan 100 mg/10 mL single-use vial for injection
50242-0053-xx	Rituxan 500 mg/50 mL single-use vial for injection
63459-103-10	rituximab-abbs injection, carton containing one 100 mg/10 mL (10 mg/mL) single-dose vial
63459-104-50	rituximab-abbs injection, carton containing one 500 mg/50 mL (10 mg/mL) single-dose vial
55513-0326-01	rituximab-arrx injection, carton containing one 100mg/10ml (10mg/ml)-single dose vial
55513-0224-01	rituximab-arrx injection, carton containing one 500 mg/50 mL (10 mg/mL) single-dose vial
00069-0238-xx	Ruxience 100 mg/10 mL single-dose vial for injection
00069-0249-xx	Ruxience 500 mg/50 mL single-dose vial for injection

ICD-10 Diagnoses

Code	Description
B20	Human immunodeficiency virus [HIV] disease
C79.32	Secondary malignant neoplasm of cerebral meninges
C81.00	Nodular lymphocyte predominant Hodgkin lymphoma, unspecified site
C81.01	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of head, face, and neck
C81.02	Nodular lymphocyte predominant Hodgkin lymphoma, intrathoracic lymph nodes
C81.03	Nodular lymphocyte predominant Hodgkin lymphoma, intra-abdominal lymph nodes
C81.04	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.05	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C81.06	Nodular lymphocyte predominant Hodgkin lymphoma, intrapelvic lymph nodes
C81.07	Nodular lymphocyte predominant Hodgkin lymphoma, spleen
C81.08	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of multiple sites
C81.09	Nodular lymphocyte predominant Hodgkin lymphoma, extranodal and solid organ sites
C82.00	Follicular lymphoma grade I, unspecified site
C82.01	Follicular lymphoma grade I, lymph nodes of head, face and neck
C82.02	Follicular lymphoma, grade I, intrathoracic lymph nodes
C82.03	Follicular lymphoma grade I, intra-abdominal lymph nodes
C82.04	Follicular lymphoma grade I, lymph nodes of axilla and upper limb
C82.05	Follicular lymphoma grade I, lymph nodes of inguinal regional and lower limb
C82.06	Follicular lymphoma grade I, intrapelvic lymph nodes
C82.07	Follicular lymphoma grade I, spleen
C82.08	Follicular lymphoma grade I, lymph nodes of multiple sites
C82.09	Follicular lymphoma grade I, extranodal and solid organ sites
C82.10	Follicular lymphoma grade II, unspecified site
C82.11	Follicular lymphoma grade II, lymph nodes of head, face and neck
C82.12	Follicular lymphoma, grade II, intrathoracic lymph nodes
C82.13	Follicular lymphoma grade II, intra-abdominal lymph nodes
C82.14	Follicular lymphoma grade II, lymph nodes of axilla and upper limb
C82.15	Follicular lymphoma grade II, lymph nodes of inguinal region and lower limb

C82.16	Follicular lymphoma grade II, intrapelvic lymph nodes
C82.17	Follicular lymphoma grade II, spleen
C82.18	Follicular lymphoma grade II, lymph nodes of multiple sites
C82.19	Follicular lymphoma grade II, extranodal and solid organ sites
C82.20	Follicular lymphoma grade III, unspecified, unspecified site
C82.21	Follicular lymphoma grade III, unspecified, lymph nodes of head, face and neck
C82.22	Follicular lymphoma, grade III, unspecified, intrathoracic lymph nodes
C82.23	Follicular lymphoma grade III, unspecified, intra-abdominal lymph nodes
C82.24	Follicular lymphoma grade III, unspecified, lymph nodes of axilla and upper limb
C82.25	Follicular lymphoma grade III, unspecified, lymph nodes of inguinal region and lower limb
C82.26	Follicular lymphoma grade III, unspecified, intrapelvic lymph nodes
C82.27	Follicular lymphoma grade III, unspecified, spleen
C82.28	Follicular lymphoma grade III, unspecified, lymph nodes of multiple sites
C82.29	Follicular lymphoma grade III, unspecified, extranodal and solid organ sites
C82.30	Follicular lymphoma grade IIIa, unspecified site
C82.31	Follicular lymphoma grade IIIa, lymph nodes of head, face and neck
C82.32	Follicular lymphoma, grade IIIa, intrathoracic lymph nodes
C82.33	Follicular lymphoma grade IIIa, intra-abdominal lymph nodes
C82.34	Follicular lymphoma grade IIIa, lymph nodes of axilla and upper limb
C82.35	Follicular lymphoma grade IIIa, lymph nodes of inguinal region and lower limb
C82.36	Follicular lymphoma grade IIIa, intrapelvic lymph nodes
C82.37	Follicular lymphoma grade IIIa, spleen
C82.38	Follicular lymphoma grade IIIa, lymph nodes of multiple sites
C82.39	Follicular lymphoma grade IIIa, extranodal and solid organ sites
C82.40	Follicular lymphoma grade IIIb, unspecified site
C82.41	Follicular lymphoma grade IIIb, lymph nodes of head, face and neck
C82.42	Follicular lymphoma, grade IIIb, intrathoracic lymph nodes
C82.43	Follicular lymphoma grade IIIb, intra-abdominal lymph nodes
C82.44	Follicular lymphoma grade IIIb, lymph nodes of axilla and upper limb
C82.45	Follicular lymphoma grade IIIb, lymph nodes of inguinal region and lower limb
C82.46	Follicular lymphoma grade IIIb, intrapelvic lymph nodes
C82.47	Follicular lymphoma grade IIIb, spleen
C82.48	Follicular lymphoma grade IIIb, lymph nodes of multiple sites
C82.49	Follicular lymphoma grade IIIb, extranodal and solid organ sites
C82.50	Diffuse follicle center lymphoma, unspecified site
C82.51	Diffuse follicle center lymphoma, lymph nodes of head, face and neck
C82.52	Diffuse follicle center lymphoma, intrathoracic lymph nodes
C82.53	Diffuse follicle center lymphoma, intra-abdominal lymph nodes
C82.54	Diffuse follicle center lymphoma, lymph nodes of axilla and upper limb
C82.55	Diffuse follicle center lymphoma, lymph nodes of inguinal region and lower limb
C82.56	Diffuse follicle center lymphoma, intrapelvic lymph nodes
C82.57	Diffuse follicle center lymphoma, spleen
C82.58	Diffuse follicle center lymphoma, lymph nodes of multiple sites
C82.59	Diffuse follicle center lymphoma, extranodal and solid organ sites
C82.60	Cutaneous follicle center lymphoma, unspecified site
C82.61	Cutaneous follicle center lymphoma, lymph nodes of head, face and neck

C82.62	Cutaneous follicle center lymphoma, intrathoracic lymph nodes
C82.63	Cutaneous follicle center lymphoma, intra-abdominal lymph nodes
C82.64	Cutaneous follicle center lymphoma, lymph nodes of axilla and upper limb
C82.65	Cutaneous follicle center lymphoma, lymph nodes of inguinal region and lower limb
C82.66	Cutaneous follicle center lymphoma, intrapelvic lymph nodes
C82.67	Cutaneous follicle center lymphoma, spleen
C82.68	Cutaneous follicle center lymphoma, lymph nodes of multiple sites
C82.69	Cutaneous follicle center lymphoma, extranodal and solid organ sites
C82.80	Other types of follicular lymphoma, unspecified site
C82.81	Other types of follicular lymphoma, lymph nodes of head, face and neck
C82.82	Other types of follicular lymphoma, intrathoracic lymph nodes
C82.83	Other types of follicular lymphoma, intra-abdominal lymph nodes
C82.84	Other types of follicular lymphoma, lymph nodes of axilla and upper limb
C82.85	Other types of follicular lymphoma, lymph nodes of inguinal region and lower limb
C82.86	Other types of follicular lymphoma, intrapelvic lymph nodes
C82.87	Other types of follicular lymphoma, spleen
C82.88	Other types of follicular lymphoma, lymph nodes of multiple sites
C82.89	Other types of follicular lymphoma, extranodal and solid organ sites
C82.90	Follicular lymphoma, unspecified, unspecified site
C82.91	Follicular lymphoma, unspecified, lymph nodes of head, face and neck
C82.92	Follicular lymphoma, unspecified, intrathoracic lymph nodes
C82.93	Follicular lymphoma, unspecified, intra-abdominal lymph nodes
C82.94	Follicular lymphoma, unspecified, lymph nodes of axilla and upper limb
C82.95	Follicular lymphoma, unspecified lymph nodes of inguinal region and lower limb
C82.96	Follicular lymphoma, unspecified, intrapelvic lymph nodes
C82.97	Follicular lymphoma, unspecified, spleen
C82.98	Follicular lymphoma, unspecified, lymph nodes of multiple sites
C82.99	Follicular lymphoma, unspecified, extranodal and solid organ sites
C83.00	Small cell B-cell lymphoma, unspecified site
C83.01	Small cell B-cell lymphoma, lymph nodes of head, face and neck
C83.02	Small cell B-cell lymphoma, intrathoracic lymph nodes
C83.03	Small cell B-cell lymphoma, intra-abdominal lymph nodes
C83.04	Small cell B-cell lymphoma, lymph nodes of axilla and upper limb
C83.05	Small cell B-cell lymphoma, lymph nodes of inguinal region and lower limb
C83.06	Small cell B-cell lymphoma, intrapelvic lymph nodes
C83.07	Small cell B-cell lymphoma, spleen
C83.08	Small cell B-cell lymphoma, lymph nodes of multiple sites
C83.09	Small cell B-cell lymphoma, extranodal and solid organ sites
C83.10	Mantle cell lymphoma, unspecified site
C83.11	Mantle cell lymphoma, lymph nodes of head, face and neck
C83.12	Mantle cell lymphoma, intrathoracic lymph nodes
C83.13	Mantle cell lymphoma, intra-abdominal lymph nodes
C83.14	Mantle cell lymphoma, lymph nodes of axilla and upper limb
C83.15	Mantle cell lymphoma, lymph nodes of inguinal region and lower limb
C83.16	Mantle cell lymphoma, intrapelvic lymph nodes
C83.17	Mantle cell lymphoma, spleen

C83.18	Mantle cell lymphoma, lymph nodes of multiple sites
C83.19	Mantle cell lymphoma, extranodal and solid organ sites
C83.30	Diffuse large B-cell lymphoma unspecified site
C83.31	Diffuse large B-cell lymphoma, lymph nodes of head, face, and neck
C83.32	Diffuse large B-cell lymphoma intrathoracic lymph nodes
C83.33	Diffuse large B-cell lymphoma intra-abdominal lymph nodes
C83.34	Diffuse large B-cell lymphoma lymph nodes of axilla and upper limb
C83.35	Diffuse large B-cell lymphoma, lymph nodes of inguinal region and lower limb
C83.36	Diffuse large B-cell lymphoma intrapelvic lymph nodes
C83.37	Diffuse large B-cell lymphoma, spleen
C83.38	Diffuse large B-cell lymphoma lymph nodes of multiple sites
C83.39	Diffuse large B-cell lymphoma extranodal and solid organ sites
C83.70	Burkitt lymphoma, unspecified site
C83.71	Burkitt lymphoma, lymph nodes of head, face, and neck
C83.72	Burkitt lymphoma, intrathoracic lymph nodes
C83.73	Burkitt lymphoma, intra-abdominal lymph nodes
C83.74	Burkitt lymphoma, lymph nodes of axilla and upper limb
C83.75	Burkitt lymphoma, lymph nodes of inguinal region and lower limb
C83.76	Burkitt lymphoma, intrapelvic lymph nodes
C83.77	Burkitt lymphoma, spleen
C83.78	Burkitt lymphoma, lymph nodes of multiple sites
C83.79	Burkitt lymphoma, extranodal and solid organ sites
C83.80	Other non-follicular lymphoma, unspecified site
C83.81	Other non-follicular lymphoma, lymph nodes of head, face and neck
C83.82	Other non-follicular lymphoma, intrathoracic lymph nodes
C83.83	Other non-follicular lymphoma, intra-abdominal lymph nodes
C83.84	Other non-follicular lymphoma, lymph nodes of axilla and upper limb
C83.85	Other non-follicular lymphoma, lymph nodes of inguinal region and lower limb
C83.86	Other non-follicular lymphoma, intrapelvic lymph nodes
C83.87	Other non-follicular lymphoma, spleen
C83.88	Other non-follicular lymphoma, lymph nodes of multiple sites
C83.89	Other non-follicular lymphoma, extranodal and solid organ sites
C83.90	Non-follicular (diffuse) lymphoma, unspecified site
C83.91	Non-follicular (diffuse) lymphoma, unspecified lymph nodes of head, face, and neck
C83.92	Non-follicular (diffuse) lymphoma, unspecified intrathoracic lymph nodes
C83.93	Non-follicular (diffuse) lymphoma, unspecified intra-abdominal lymph nodes
C83.94	Non-follicular (diffuse) lymphoma, unspecified lymph nodes of axilla and upper limb
C83.95	Non-follicular (diffuse) lymphoma, unspecified lymph nodes of inguinal region and lower limb
C83.96	Non-follicular (diffuse) lymphoma, unspecified intrapelvic lymph nodes
C83.97	Non-follicular (diffuse) lymphoma, unspecified spleen
C83.98	Non-follicular (diffuse) lymphoma, unspecified lymph nodes of multiple sites
C83.99	Non-follicular (diffuse) lymphoma, unspecified extranodal and solid organ sites
C85.20	Mediastinal (thymic) large B-cell lymphoma, unspecified site
C85.21	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of head, face and neck
C85.22	Mediastinal (thymic) large B-cell lymphoma, intrathoracic lymph nodes
C85.23	Mediastinal (thymic) large B-cell lymphoma, intra-abdominal lymph nodes

C85.24	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of axilla and upper limb
C85.25	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of inguinal region and lower limb
C85.26	Mediastinal (thymic) large B-cell lymphoma, intrapelvic lymph nodes
C85.27	Mediastinal (thymic) large B-cell lymphoma, spleen
C85.28	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of multiple sites
C85.29	Mediastinal (thymic) large B-cell lymphoma, extranodal and solid organ sites
C85.80	Other specified types of non-Hodgkin lymphoma, unspecified site
C85.81	Other specified types of non-Hodgkin lymphoma, lymph nodes of head, face and neck
C85.82	Other specified types of non-Hodgkin lymphoma, intrathoracic lymph nodes
C85.83	Other specified types of non-Hodgkin lymphoma, intra-abdominal lymph nodes
C85.84	Other specified types of non-Hodgkin lymphoma, lymph nodes of axilla and upper limb
C85.85	Other specified types of non-Hodgkin lymphoma, lymph nodes of inguinal region of lower limb
C85.86	Other specified types of non-Hodgkin lymphoma, intrapelvic lymph nodes
C85.87	Other specified types of non-Hodgkin lymphoma, spleen
C85.88	Other specified types of non-Hodgkin lymphoma, lymph nodes of multiple sites
C85.89	Other specified types of non-Hodgkin lymphoma, extranodal and solid organ sites
C88.0	Waldenström macroglobulinemia
C88.4	Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT-lymphoma)
C91.00	Acute lymphoblastic leukemia not having achieved remission
C91.01	Acute lymphoblastic leukemia, in remission
C91.02	Acute lymphoblastic leukemia, in relapse
C91.1	Chronic lymphocytic leukemia of B-cell type
C91.10	Chronic lymphocytic leukemia of B-cell type not having achieved remission
C91.12	Chronic lymphocytic leukemia of B-cell type in relapse
C91.40	Hairy cell leukemia not having achieved remission
C91.42	Hairy cell leukemia, in relapse
D36.0	Benign neoplasm of lymph nodes
D47.Z1	Post-transplant lymphoproliferative disorder (PTLD)
D47.Z2	Other neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue-Castleman disease
D59.1	Other autoimmune hemolytic anemias
D69.3	Immune thrombocytopenic purpura
D69.41	Evans Syndrome
D69.42	Congenital and hereditary thrombocytopenia purpura
D69.49	Other primary thrombocytopenia
D89.811	Chronic graft-versus-host disease
G04.81	Other encephalitis and encephalomyelitis
L10.0	Pemphigus vulgaris
M05.10	Rheumatoid lung disease with rheumatoid arthritis of unspecified site
M05.111	Rheumatoid lung disease with rheumatoid arthritis of right shoulder
M05.112	Rheumatoid lung disease with rheumatoid arthritis of left shoulder
M05.119	Rheumatoid lung disease with rheumatoid arthritis of unspecified shoulder
M05.121	Rheumatoid lung disease with rheumatoid arthritis of right elbow
M05.122	Rheumatoid lung disease with rheumatoid arthritis of left elbow
M05.129	Rheumatoid lung disease with rheumatoid arthritis of unspecified elbow
M05.131	Rheumatoid lung disease with rheumatoid arthritis of right wrist
M05.132	Rheumatoid lung disease with rheumatoid arthritis of left wrist

M05.139	Rheumatoid lung disease with rheumatoid arthritis of unspecified wrist
M05.141	Rheumatoid lung disease with rheumatoid arthritis of right hand
M05.142	Rheumatoid lung disease with rheumatoid arthritis of left hand
M05.149	Rheumatoid lung disease with rheumatoid arthritis of unspecified hand
M05.151	Rheumatoid lung disease with rheumatoid arthritis of right hip
M05.152	Rheumatoid lung disease with rheumatoid arthritis of left hip
M05.159	Rheumatoid lung disease with rheumatoid arthritis of unspecified hip
M05.161	Rheumatoid lung disease with rheumatoid arthritis of right knee
M05.162	Rheumatoid lung disease with rheumatoid arthritis of left knee
M05.169	Rheumatoid lung disease with rheumatoid arthritis of unspecified knee
M05.171	Rheumatoid lung disease with rheumatoid arthritis of right ankle and foot
M05.172	Rheumatoid lung disease with rheumatoid arthritis of left ankle and foot
M05.179	Rheumatoid lung disease with rheumatoid arthritis of unspecified ankle and foot
M05.19	Rheumatoid lung disease with rheumatoid arthritis of multiple sites
M05.20	Rheumatoid vasculitis with rheumatoid arthritis of unspecified site
M05.211	Rheumatoid vasculitis with rheumatoid arthritis of right shoulder
M05.212	Rheumatoid vasculitis with rheumatoid arthritis of left shoulder
M05.219	Rheumatoid vasculitis with rheumatoid arthritis of unspecified shoulder
M05.221	Rheumatoid vasculitis with rheumatoid arthritis of right elbow
M05.222	Rheumatoid vasculitis with rheumatoid arthritis of left elbow
M05.229	Rheumatoid vasculitis with rheumatoid arthritis of unspecified elbow
M05.231	Rheumatoid vasculitis with rheumatoid arthritis of right wrist
M05.232	Rheumatoid vasculitis with rheumatoid arthritis of left wrist
M05.239	Rheumatoid vasculitis with rheumatoid arthritis of unspecified wrist
M05.241	Rheumatoid vasculitis with rheumatoid arthritis of right hand
M05.242	Rheumatoid vasculitis with rheumatoid arthritis of left hand
M05.249	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hand
M05.251	Rheumatoid vasculitis with rheumatoid arthritis of right hip
M05.252	Rheumatoid vasculitis with rheumatoid arthritis of left hip
M05.259	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hip
M05.261	Rheumatoid vasculitis with rheumatoid arthritis of right knee
M05.262	Rheumatoid vasculitis with rheumatoid arthritis of left knee
M05.269	Rheumatoid vasculitis with rheumatoid arthritis of unspecified knee
M05.271	Rheumatoid vasculitis with rheumatoid arthritis of right ankle and foot
M05.272	Rheumatoid vasculitis with rheumatoid arthritis of left ankle and foot
M05.279	Rheumatoid vasculitis with rheumatoid arthritis of unspecified ankle and foot
M05.29	Rheumatoid vasculitis with rheumatoid arthritis of multiple sites
M05.30	Rheumatoid heart disease with rheumatoid arthritis of unspecified site
M05.311	Rheumatoid heart disease with rheumatoid arthritis of right shoulder
M05.312	Rheumatoid heart disease with rheumatoid arthritis of left shoulder
M05.319	Rheumatoid heart disease with rheumatoid arthritis of unspecified shoulder
M05.321	Rheumatoid heart disease with rheumatoid arthritis of right elbow
M05.322	Rheumatoid heart disease with rheumatoid arthritis of left elbow
M05.329	Rheumatoid heart disease with rheumatoid arthritis of unspecified elbow
M05.331	Rheumatoid heart disease with rheumatoid arthritis of right wrist
M05.332	Rheumatoid heart disease with rheumatoid arthritis of left wrist

M05.339	Rheumatoid heart disease with rheumatoid arthritis of unspecified wrist
M05.341	Rheumatoid heart disease with rheumatoid arthritis of right hand
M05.342	Rheumatoid heart disease with rheumatoid arthritis of left hand
M05.349	Rheumatoid heart disease with rheumatoid arthritis of unspecified hand
M05.351	Rheumatoid heart disease with rheumatoid arthritis of right hip
M05.352	Rheumatoid heart disease with rheumatoid arthritis of left hip
M05.359	Rheumatoid heart disease with rheumatoid arthritis of unspecified hip
M05.361	Rheumatoid heart disease with rheumatoid arthritis of right knee
M05.362	Rheumatoid heart disease with rheumatoid arthritis of left knee
M05.369	Rheumatoid heart disease with rheumatoid arthritis of unspecified knee
M05.371	Rheumatoid heart disease with rheumatoid arthritis of right ankle and foot
M05.372	Rheumatoid heart disease with rheumatoid arthritis of left ankle and foot
M05.379	Rheumatoid heart disease with rheumatoid arthritis of unspecified ankle and foot
M05.39	Rheumatoid heart disease with rheumatoid arthritis of multiple sites
M05.40	Rheumatoid myopathy with rheumatoid arthritis of unspecified site
M05.411	Rheumatoid myopathy with rheumatoid arthritis of right shoulder
M05.412	Rheumatoid myopathy with rheumatoid arthritis of left shoulder
M05.419	Rheumatoid myopathy with rheumatoid arthritis of unspecified shoulder
M05.421	Rheumatoid myopathy with rheumatoid arthritis of right elbow
M05.422	Rheumatoid myopathy with rheumatoid arthritis of left elbow
M05.429	Rheumatoid myopathy with rheumatoid arthritis of unspecified elbow
M05.431	Rheumatoid myopathy with rheumatoid arthritis of right wrist
M05.432	Rheumatoid myopathy with rheumatoid arthritis of left wrist
M05.439	Rheumatoid myopathy with rheumatoid arthritis of unspecified wrist
M05.441	Rheumatoid myopathy with rheumatoid arthritis of right hand
M05.442	Rheumatoid myopathy with rheumatoid arthritis of left hand
M05.449	Rheumatoid myopathy with rheumatoid arthritis of unspecified hand
M05.451	Rheumatoid myopathy with rheumatoid arthritis of right hip
M05.452	Rheumatoid myopathy with rheumatoid arthritis of left hip
M05.459	Rheumatoid myopathy with rheumatoid arthritis of unspecified hip
M05.461	Rheumatoid myopathy with rheumatoid arthritis of right knee
M05.462	Rheumatoid myopathy with rheumatoid arthritis of left knee
M05.469	Rheumatoid myopathy with rheumatoid arthritis of unspecified knee
M05.471	Rheumatoid myopathy with rheumatoid arthritis of right ankle and foot
M05.472	Rheumatoid myopathy with rheumatoid arthritis of left ankle and foot
M05.479	Rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot
M05.49	Rheumatoid myopathy with rheumatoid arthritis of multiple sites
M05.50	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified site
M05.511	Rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder
M05.512	Rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder
M05.519	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified shoulder
M05.521	Rheumatoid polyneuropathy with rheumatoid arthritis of right elbow
M05.522	Rheumatoid polyneuropathy with rheumatoid arthritis of left elbow
M05.529	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified elbow
M05.531	Rheumatoid polyneuropathy with rheumatoid arthritis of right wrist
M05.532	Rheumatoid polyneuropathy with rheumatoid arthritis of left wrist

M05.539	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified wrist
M05.541	Rheumatoid polyneuropathy with rheumatoid arthritis of right hand
M05.542	Rheumatoid polyneuropathy with rheumatoid arthritis of left hand
M05.549	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hand
M05.551	Rheumatoid polyneuropathy with rheumatoid arthritis of right hip
M05.552	Rheumatoid polyneuropathy with rheumatoid arthritis of left hip
M05.559	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hip
M05.561	Rheumatoid polyneuropathy with rheumatoid arthritis of right knee
M05.562	Rheumatoid polyneuropathy with rheumatoid arthritis of left knee
M05.569	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified knee
M05.571	Rheumatoid polyneuropathy with rheumatoid arthritis of right ankle and foot
M05.572	Rheumatoid polyneuropathy with rheumatoid arthritis of left ankle and foot
M05.579	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified ankle and foot
M05.59	Rheumatoid polyneuropathy with rheumatoid arthritis of multiple sites
M05.60	Rheumatoid arthritis of unspecified site with involvement of other organs and systems
M05.611	Rheumatoid arthritis of right shoulder with involvement of other organs and systems
M05.612	Rheumatoid arthritis of left shoulder with involvement of other organs and systems
M05.619	Rheumatoid arthritis of unspecified shoulder with involvement of other organs and systems
M05.621	Rheumatoid arthritis of right elbow with involvement of other organs and systems
M05.622	Rheumatoid arthritis of left elbow with involvement of other organs and systems
M05.629	Rheumatoid arthritis of unspecified elbow with involvement of other organs and systems
M05.631	Rheumatoid arthritis of right wrist with involvement of other organs and systems
M05.632	Rheumatoid arthritis of left wrist with involvement of other organs and systems
M05.639	Rheumatoid arthritis of unspecified wrist with involvement of other organs and systems
M05.641	Rheumatoid arthritis of right hand with involvement of other organs and systems
M05.642	Rheumatoid arthritis of left hand with involvement of other organs and systems
M05.649	Rheumatoid arthritis of unspecified hand with involvement of other organs and systems
M05.651	Rheumatoid arthritis of right hip with involvement of other organs and systems
M05.652	Rheumatoid arthritis of left hip with involvement of other organs and systems
M05.659	Rheumatoid arthritis of unspecified hip with involvement of other organs and systems
M05.661	Rheumatoid arthritis of right knee with involvement of other organs and systems
M05.662	Rheumatoid arthritis of left knee with involvement of other organs and systems
M05.669	Rheumatoid arthritis of unspecified knee with involvement of other organs and systems
M05.671	Rheumatoid arthritis of right ankle and foot with involvement of other organs and systems
M05.672	Rheumatoid arthritis of left ankle and foot with involvement of other organs and systems
M05.679	Rheumatoid arthritis of unspecified ankle and foot with involvement of other organs and systems
M05.69	Rheumatoid arthritis of multiple sites with involvement of other organs and systems
M05.70	Rheumatoid arthritis with rheumatoid factor of unspecified site without organ or systems involvement
M05.711	Rheumatoid arthritis with rheumatoid factor of right shoulder without organ or systems involvement
M05.712	Rheumatoid arthritis with rheumatoid factor of left shoulder without organ or systems involvement
M05.719	Rheumatoid arthritis with rheumatoid factor of unspecified shoulder without organ or systems involvement
M05.721	Rheumatoid arthritis with rheumatoid factor of right elbow without organ or systems involvement
M05.722	Rheumatoid arthritis with rheumatoid factor of left elbow without organ or systems involvement
M05.729	Rheumatoid arthritis with rheumatoid factor of unspecified elbow without organ or systems involvement
M05.731	Rheumatoid arthritis with rheumatoid factor of right wrist without organ or systems involvement

M05.732	Rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems involvement
M05.739	Rheumatoid arthritis with rheumatoid factor of unspecified wrist without organ or systems involvement
M05.741	Rheumatoid arthritis with rheumatoid factor of right hand without organ or systems involvement
M05.742	Rheumatoid arthritis with rheumatoid factor of left hand without organ or systems involvement
M05.749	Rheumatoid arthritis with rheumatoid factor of unspecified hand without organ or systems involvement
M05.751	Rheumatoid arthritis with rheumatoid factor of right hip without organ or systems involvement
M05.752	Rheumatoid arthritis with rheumatoid factor of left hip without organ or systems involvement
M05.759	Rheumatoid arthritis with rheumatoid factor of unspecified hip without organ or systems involvement
M05.761	Rheumatoid arthritis with rheumatoid factor of right knee without organ or systems involvement
M05.762	Rheumatoid arthritis with rheumatoid factor of left knee without organ or systems involvement
M05.769	Rheumatoid arthritis with rheumatoid factor of unspecified knee without organ or systems involvement
M05.771	Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems involvement
M05.772	Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems involvement
M05.779	Rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot without organ or systems involvement
M05.79	Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement
M05.80	Other rheumatoid arthritis with rheumatoid factor of unspecified site
M05.811	Other rheumatoid arthritis with rheumatoid factor of right shoulder
M05.812	Other rheumatoid arthritis with rheumatoid factor of left shoulder
M05.819	Other rheumatoid arthritis with rheumatoid factor of unspecified shoulder
M05.821	Other rheumatoid arthritis with rheumatoid factor of right elbow
M05.822	Other rheumatoid arthritis with rheumatoid factor of left elbow
M05.829	Other rheumatoid arthritis with rheumatoid factor of unspecified elbow
M05.831	Other rheumatoid arthritis with rheumatoid factor of right wrist
M05.832	Other rheumatoid arthritis with rheumatoid factor of left wrist
M05.839	Other rheumatoid arthritis with rheumatoid factor of unspecified wrist
M05.841	Other rheumatoid arthritis with rheumatoid factor of right hand
M05.842	Other rheumatoid arthritis with rheumatoid factor of left hand
M05.849	Other rheumatoid arthritis with rheumatoid factor of unspecified hand
M05.851	Other rheumatoid arthritis with rheumatoid factor of right hip
M05.852	Other rheumatoid arthritis with rheumatoid factor of left hip
M05.859	Other rheumatoid arthritis with rheumatoid factor of unspecified hip
M05.861	Other rheumatoid arthritis with rheumatoid factor of right knee
M05.862	Other rheumatoid arthritis with rheumatoid factor of left knee
M05.869	Other rheumatoid arthritis with rheumatoid factor of unspecified knee
M05.871	Other rheumatoid arthritis with rheumatoid factor of right ankle and foot
M05.872	Other rheumatoid arthritis with rheumatoid factor of left ankle and foot
M05.879	Other rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot
M05.89	Other rheumatoid arthritis with rheumatoid factor of multiple sites
M05.9	Rheumatoid arthritis with rheumatoid factor, unspecified
M06.00	Rheumatoid arthritis without rheumatoid factor, unspecified site
M06.011	Rheumatoid arthritis without rheumatoid factor, right shoulder
M06.012	Rheumatoid arthritis without rheumatoid factor, left shoulder

M06.019	Rheumatoid arthritis without rheumatoid factor, unspecified shoulder
M06.021	Rheumatoid arthritis without rheumatoid factor, right elbow
M06.022	Rheumatoid arthritis without rheumatoid factor, left elbow
M06.029	Rheumatoid arthritis without rheumatoid factor, unspecified elbow
M06.031	Rheumatoid arthritis without rheumatoid factor, right wrist
M06.032	Rheumatoid arthritis without rheumatoid factor, left wrist
M06.039	Rheumatoid arthritis without rheumatoid factor, unspecified wrist
M06.041	Rheumatoid arthritis without rheumatoid factor, right hand
M06.042	Rheumatoid arthritis without rheumatoid factor, left hand
M06.049	Rheumatoid arthritis without rheumatoid factor, unspecified hand
M06.051	Rheumatoid arthritis without rheumatoid factor, right hip
M06.052	Rheumatoid arthritis without rheumatoid factor, left hip
M06.059	Rheumatoid arthritis without rheumatoid factor, unspecified hip
M06.061	Rheumatoid arthritis without rheumatoid factor, right knee
M06.062	Rheumatoid arthritis without rheumatoid factor, left knee
M06.069	Rheumatoid arthritis without rheumatoid factor, unspecified knee
M06.071	Rheumatoid arthritis without rheumatoid factor, right ankle and foot
M06.072	Rheumatoid arthritis without rheumatoid factor, left ankle and foot
M06.079	Rheumatoid arthritis without rheumatoid factor, unspecified ankle and foot
M06.08	Rheumatoid arthritis without rheumatoid factor, vertebrae
M06.09	Rheumatoid arthritis without rheumatoid factor, multiple sites
M06.80	Other specified rheumatoid arthritis, unspecified site
M06.811	Other specified rheumatoid arthritis, right shoulder
M06.812	Other specified rheumatoid arthritis, left shoulder
M06.819	Other specified rheumatoid arthritis, unspecified shoulder
M06.821	Other specified rheumatoid arthritis, right elbow
M06.822	Other specified rheumatoid arthritis, left elbow
M06.829	Other specified rheumatoid arthritis, unspecified elbow
M06.831	Other specified rheumatoid arthritis, right wrist
M06.832	Other specified rheumatoid arthritis, left wrist
M06.839	Other specified rheumatoid arthritis, unspecified wrist
M06.841	Other specified rheumatoid arthritis, right hand
M06.842	Other specified rheumatoid arthritis, left hand
M06.849	Other specified rheumatoid arthritis, unspecified hand
M06.851	Other specified rheumatoid arthritis, right hip
M06.852	Other specified rheumatoid arthritis, left hip
M06.859	Other specified rheumatoid arthritis, unspecified hip
M06.861	Other specified rheumatoid arthritis, right knee
M06.862	Other specified rheumatoid arthritis, left knee
M06.869	Other specified rheumatoid arthritis, unspecified knee
M06.871	Other specified rheumatoid arthritis, right ankle and foot
M06.872	Other specified rheumatoid arthritis, left ankle and foot
M06.879	Other specified rheumatoid arthritis, unspecified ankle and foot
M06.88	Other specified rheumatoid arthritis, vertebrae
M06.89	Other specified rheumatoid arthritis, multiple sites
M06.9	Rheumatoid arthritis, unspecified

M31.1	Thrombotic microangiopathy
M31.30	Wegener's granulomatosis without renal involvement
M31.31	Wegener's granulomatosis with renal involvement
M31.7	Microscopic polyangiitis
R59.0	Localized enlarged lymph nodes
R59.1	Generalized enlarged lymph nodes
R59.9	Enlarged lymph nodes, unspecified
Z85.71	Personal history of Hodgkin lymphoma
Z85.72	Personal history of non-Hodgkin lymphomas
Z85.79	Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues

Revision History

Company(ies)	DATE	REVISION
EmblemHealth & ConnectiCare	8/18/2023	<p>Annual Review:</p> <p><u>Length of Authorization:</u> Added "Adult Acute Lymphoblastic Leukemia (ALL) may be renewed for a maximum of 18 doses. o Mantle Cell Lymphoma may be renewed until disease progression or intolerable toxicity. o Hairy Cell Leukemia may NOT be renewed. o Induction/Consolidation of Pediatric B-Cell Acute Leukemia and Aggressive Mature B-Cell Lymphomas may NOT be renewed. o Pediatric Hodgkin Lymphoma may NOT be renewed.</p> <ul style="list-style-type: none"> Management of Immunotherapy-Related Toxicities: <ul style="list-style-type: none"> o Myositis/Myasthenia Gravis/Encephalitis may NOT be renewed. o Bullous Dermatitis may be renewed for a maximum of 18 months (4 total doses). Chronic Graft-Versus-Host Disease (cGVHD) may NOT be renewed. Hematopoietic Cell Transplantation may NOT be renewed. Lupus Nephritis may be renewed ONLY in patients experiencing a disease relapse. Complications of Transplanted Solid Organ may NOT be renewed. Removed "Acute lymphoblastic leukemia (ALL) may not be renewed." <p><u>Updated Dosing Limits Chart</u></p> <p><u>Added: Pediatric Mature B-Cell Acute Leukemia † Indication and criteria</u></p> <p><u>Acute Lymphoblastic Leukemia (ALL) ‡ Initial Criteria:</u></p> <p>Removed "Patient's disease is Philadelphia chromosome-positive (Ph+) and refractory to tyrosine kinase inhibitors (e.g. omacetaxine, imatinib, bosutinib, ponatinib, nilotinib, etc.)"</p>

		<p><u>CNS Cancer ‡ Initial Criteria</u></p> <p>Removed: “Rituximab will be administered intrathecally; OR:</p> <p>Also Removed “Patient will receive in combination with a methotrexate-containing regimen as a component of induction therapy and/or consolidation therapy with a complete response to induction therapy; OR</p> <p>iv. Patient has relapsed or refractory disease and will receive rituximab as a single agent, or in combination with temozolomide, lenalidomide or high-dose methotrexate”</p> <p>Added “Used for induction therapy; AND</p> <p>a. Used as a single agent OR in combination with a methotrexate-containing regimen, temozolomide, or lenalidomide‡; OR</p> <p>b. Patient has CSF positive or spinal MRI positive disease§; OR</p> <p>v. Used for consolidation (monthly maintenance) therapy; AND</p> <p>a. Used as continuation of induction regimen in patients with complete response or complete response unconfirmed (CRu) to induction therapy; AND</p> <p>1.)Used as a single agent§; OR</p> <p>2.)Used on combination with high-dose methotrexate‡; OR</p> <p>vi. Used for relapsed or refractory disease; AND</p> <p>a. Used as a single agent OR in combination with systemic therapy in patients with prior whole brain radiation therapy§; AND</p> <p>1.)Patient has CSF positive or spinal MRI positive disease; OR</p> <p>b. Used as a single agent OR in combination with temozolomide, lenalidomide, or highdose methotrexate‡</p> <p><i>§ For intrathecal administration ONLY; ‡ For intravenous administration ONLY”</i></p> <p><u>Non-Hodgkin’s lymphomas (NHL) † Initial Criteria:</u></p> <p>Added “<u>Extranodal Marginal Zone Lymphoma (EMZL) of the Stomach & Nongastric Sites (Noncutaneous)</u> ‡</p> <p>11. High-Grade B-Cell Lymphomas ‡”</p> <p>12. Removed “Gastric & Non-Gastric MALT Lymphoma ‡</p> <p>13. Hairy Cell Leukemia ‡</p> <p>a. Used for relapsed or refractory disease”</p> <p>b. “Patient has had solid organ transplant or allogeneic hematopoietic stem cell transplantation</p> <p>14. Primary Cutaneous B-Cell Lymphomas ‡</p> <p>a. Used for generalized (skin only), marginal zone or follicle center disease”</p>
--	--	---

	<p><u>Management of Immunotherapy-Related Toxicities Initial Criteria:</u></p> <p>Added “cemiplimab” “ipilimumab, dostarlimab, nivolumab/relatlimab-rmbw “ to the Statement: Patient has been receiving therapy with an immune checkpoint inhibitor (e.g. cemiplimab ,nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, ipilimumab, dostarlimab, nivolumab/relatlimab-rmbw etc.); AND</p> <p>Removed “non-viral” from the following statement: Patient has non-viral encephalitis related to their immunotherapy; AND</p> <p>Removed “Patient is refractory to methylprednisolone and/or IV immunoglobulin (IVIG)”</p> <p>Added “Patient has had limited to no improvement after 7 to 14 days on pulse-dose corticosteroids with or without intravenous immunoglobulin (IVIG); OR</p> <p>9. Patient has bullous dermatitis related to immunotherapy; AND</p> <p style="padding-left: 40px;">b. Used as additional therapy for moderate (G2), severe (G3) or life-threatening (G4) disease; OR</p> <p>10. Patient has moderate, severe, or life-threatening steroid-refractory myositis (proximal muscle weakness, neck flexor weakness, with or without myalgias) related to immunotherapy; AND</p> <p style="padding-left: 40px;">b. Used for significant dysphagia, life-threatening situations, or cases refractory to corticosteroids; OR</p> <p>11. Patient has myasthenia gravis related to immunotherapy; AND</p> <p style="padding-left: 40px;">b. Used as additional therapy for severe (G3-4) disease that is refractory to plasmapheresis or IVIG”</p> <p><u>Pemphigus vulgaris Initial Criteria:</u></p> <p>Added “Positive direct immunofluorescence (DIF) microscopy result OR “</p> <p>Removed “or indirect” from the Statement: Presence of autoantibodies as detected by direct or indirect immunofluorescence” and added “ or enzyme-linked immunosorbent assay (ELISA); AND”</p> <p><u>Thrombocytopenic purpura ‡ Initial Criteria:</u></p> <p>Removed “Congenital and hereditary thrombocytopenic purpura</p> <p style="padding-left: 40px;">d. Thrombotic thrombocytopenic purpura in patients with ADAMTS13-deficiency”</p> <p>Added “Patient has previously failed or has a contraindication or intolerance to therapy with corticosteroids; AND</p> <p style="padding-left: 40px;">3. Patient is at increased risk for bleeding as indicated by platelet count (within the previous</p> <p style="padding-left: 80px;">28 days) less than $30 \times 10^9/L$ ($30,000/mm^3$)”</p> <p><u>Chronic graft-versus-host disease (cGVHD) ‡ Initial Criteria:</u></p> <p>Removed “Patient has failed one or more previous lines of systemic therapy for the treatment of cGVHD (e.g., corticosteroids or immunosuppressants such as cyclosporine); AND”</p>
--	---

		<p>Added "Used as additional therapy in combination with corticosteroids; AND</p> <p>5. Patient has no response (e.g., steroid-refractory disease) to first-line therapy options; AND"</p> <p><u>Renewal Criteria:</u></p> <p>Removed "Thrombotic thrombocytopenic purpura (TTP) Disease response as indicated by an increase in ADAMTS13 activity with a reduction in thrombosis risk"</p> <p><u>Granulomatosis with Polyangiitis (GPA) (Wegener's granulomatosis) and Microscopic polyangiitis (MPA)</u></p> <p>Added "Decreased frequency in the occurrence of major relapses (defined by the reappearance of clinical and/or laboratory signs of vasculitis activity that could lead to organ failure or damage, or could be life threatening)"</p> <p><u>Chronic graft-versus-host disease (cGVHD)</u></p> <p>Removed "Disease response as indicated by improvement in patient-reported symptoms or clinician assessments (e.g., manifestations of disease to the skin, oral cavity, musculoskeletal system, etc.)"</p> <p>Added "Coverage may NOT be renewed"</p> <p>Updated <u>Dosing Chart</u></p> <p>Updated <u>Truxima Indications:</u></p> <p><u>Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA)</u></p> <p>Removed "In combination with glucocorticoids, is indicated for the treatment of adult patients with Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA)."</p> <p>Added "In combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA)"</p> <p><u>Removed "Pemphigus Vulgaris (PV)</u></p> <p>1. Treatment of adult patients with moderate to severe pemphigus vulgaris."</p> <p>Added NDCs:</p> <table border="1"> <tr> <td>00069-0238-xx</td> </tr> <tr> <td>00069-0249-xx</td> </tr> </table>	00069-0238-xx	00069-0249-xx
00069-0238-xx				
00069-0249-xx				
EmblemHealth & ConnectiCare	12/30/2022	Added FDA approved indication of Rheumatoid Arthritis to Ruxience and Riabni		
EmblemHealth & ConnectiCare	09/16/2021	Confirmed non-preferred status of Riabni; Added Q-Code (Q5123) Injection, rituximab-arrx, biosimilar, (riabni), 10 mg		
EmblemHealth & ConnectiCare	02/02/2021	Added Riabni biosimilar and its indications per FDA label		
EmblemHealth & ConnectiCare	12/19/2020	<p>Clarifications:</p> <ul style="list-style-type: none"> Step therapy will apply to NEW starts only NCCN-supported use (with 1 or 2A recommendation) will be covered <p>Renewal criteria updated:</p> <ul style="list-style-type: none"> Removed: "Patient continues to meet criteria identified above" 		

		Added coverage: "Continuation of documented current and/or successful therapy with a non-preferred agent (Rituxan)"
EmblemHealth & ConnectiCare	11/2/2020	Effective 01/01/2021 Member must fail trial of Ruxience AND Truxima, prior to using Rituxan. (Medicare members are subject to this step therapy).
EmblemHealth & ConnectiCare	06/11/2020	Added Q-Code (Q5119): Injection, rituximab-pvvr, biosimilar, 10 mg (Ruxience). Effective Date: 07/01/2020
EmblemHealth & ConnectiCare	05/07/2020	Added two newly approved indications and criteria for Truxima per FDA Label: <ul style="list-style-type: none"> Rheumatoid Arthritis (RA) Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA)
EmblemHealth & ConnectiCare	03/31/2020	Added to the Initial Approval Criteria: Effective 07/01/2020, Ruxience and Truxima are the preferred agents for Commercial and Medicaid members. Failed trial of Ruxience AND Truxima for FDA approved indications prior to using Rituxan (Only Commercial and Medicaid members are subject to this step therapy).
EmblemHealth & ConnectiCare	03/31/2020	Ruxience and Truxima indications updated per FDA label.
EmblemHealth & ConnectiCare	01/01/2020	Added Ruxience biosimilar and its indications per FDA label
EmblemHealth & ConnectiCare	10/17/2019	Updated Truxima's indications for NHL and CLL, updated dosage and administration for CLL (initial therapy), updated Non-Hodgkin's Lymphoma dosing criteria, updated dosing criteria for Granulomatosis with Polyangiitis (GPA), Wegener's Granulomatosis and Microscopic Polyangiitis (MPA), updated dosing criteria for cGVHD
EmblemHealth & ConnectiCare	07/01/2019	Added Q5115 Truxima biosimilar
EmblemHealth & ConnectiCare	12/03/2018	Added J9312 and removed J9310 from Applicable Procedure Codes.

References

1. Rituxan [package insert]. South San Francisco, CA; Genentech, Inc; Updated September 2019. Accessed December 2022.
2. Product Information: TRUXIMA® intravenous injection, rituximab-abbs intravenous injection. Teva Pharmaceuticals USA Inc (per FDA), North Wales, PA, Updated September 2019. Accessed December 2022.
3. Product Information: RUXIENCE™ intravenous injection, rituximab-pvvr intravenous injection. Pfizer Labs (per FDA), New York, NY, 2019. Accessed December 2022.
4. Product Information: RIABNI™ intravenous injection, rituximab-arrr intravenous injection. Amgen Inc (per FDA), Thousand Oaks, CA, Accessed December 2022.

5. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) rituximab. National Comprehensive Cancer Network, 2018. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc.” To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed August 2018.
6. Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. *Ann Intern Med* 2007; 146:25-33.
7. Zaja F, Baccarani M, Mazza P, et al: Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. *Blood* 2010; 115(14):2755-2762.
8. Stasi R, Pagano A, Stipa E, et al: Rituximab chimeric anati-CD10 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. *Blood* 2001; 98(4):952-957.
9. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. *Blood*. 117(16):4190-4207.
10. Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. *N Engl J Med* 2007; 357:545-52.
11. Ahmed AR, Spigelman Z, Cavacini LA et al. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. *N Engl J Med* 2006; 355:1772-9.
12. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Care Res (Hoboken)*. 2015 Nov 6. doi: 10.1002/acr.22783.
13. Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann Rheum Dis*. 2017 Mar 6. pii: annrheumdis-2016-210715.
14. González-Barca E, Domingo-Domenech E, Capote FJ, et al. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. *Haematologica*. 2007 Nov; 92(11):1489-94.
15. Chamberlain MC, Johnston SK, Van Horn A, et al. Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C. *J Neurooncol*. 2009 Feb;91(3):271-7.
16. Scully M, Cohen H, Cavenagh J, et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. *Br J Haematol* 2007;136:451-461.
17. Fakhouri F, Vernant JP, Veyradier A, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. *Blood*. 2005; 106:1932-37.
18. Elliott MA, Heit JA, Rajiv K, et al. Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature. *Eur J Haematol* 2009. Epub ahead of print, doi:10.1111/j.1600-0609.2009.01292.
19. Scully M, McDonald V, Cavenagh J, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. *Blood*. 2011;118(7):1746-1753.
20. Tun NM, Villani GM. Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis. *J Thromb Thrombolysis*. 2012;34(3):347-359.
21. Froissart A, Buffet M, Veyradier A, et al: Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. *Crit Care Med* 2012; 40(1):104-111.

22. van Dorp S, Resemann H, te Boome L, et al. The immunological phenotype of rituximab-sensitive chronic graft-versus-host disease: a phase II study. *Haematologica* 2011;96(9):1380-1384.
23. Kim SJ, Lee JW, Jung CW, et al. Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study. *Haematologica* 2010;95(11):1935-1942.
24. Cutler C, Miklos D, Kim HT, et al, "Rituximab for Steroid-Refractory Chronic Graft-Versus-Host Disease," *Blood*, 2006, 108(2):756-62.
25. Wolff D, Schleuning M, von Harsdorf S, et al. Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. *Biol Blood Marrow Transplant*. 2011 Jan;17(1):1-17. doi: 10.1016/j.bbmt.2010.05.011.
26. Frame JN, Fichtner R, McDevitt PW. Rituximab for the treatment of autoimmune hemolytic anemia (AIHA) in adults: an analysis of literature reports in 92 patients. *Blood* 2004;104: Abstract 3721.
27. Birgens H, Frederiksen H, Hasselbalch HC, et al: A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. *Br J Haematol* 2013; 163(3):393-399.
28. Schollkopf C, Kjeldsen L, Bjerrum OW, et al: Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. *Leuk Lymphoma* 2006; 47(N2):253-260.
29. Berentsen S, Ulvestad E, Gjertsen BT, et al: Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. *Blood* 2004; 103(8):2925-2928.
30. Reynaud Q, Durieu I, Dutertre M, et al. Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies. *Autoimmune Rev*. 2015;14(4):304-313.
31. Barcellini W, Zaja F, Zaninoni A, et al, "Low-dose Rituximab in Adult Patients with Idiopathic Autoimmune Hemolytic Anemia: Clinical Efficacy and Biologic Studies," *Blood*, 2012, 119(16):3691-7.
32. Roumier M, Loustau V, Guillaud C, et al. Characteristics and outcome of warm autoimmune hemolytic anemia in adults: New insights based on a single-center experience with 60 patients. *Am J Hematol*. 2014;89(9): E150-E155.
33. Gobert D, Bussel JB, Cunningham-Rundles C, et al. Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenia's: a retrospective multicentre study on 33 patients. *Br J Haematol*. 2011;155(4):498-508.
34. YW Shin, ST Lee, KI Park, et al. Treatment strategies for autoimmune encephalitis. *Ther Adv Neurol Disord*. 2017 Aug 16; 11:1756285617722347. doi: 10.1177/1756285617722347. eCollection 2018. Review.
35. Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. *J Am Acad Dermatol*. 2008 June; 58(6): 1043–1046. doi: 10.1016/j.jaad.2008.01.012. Avail at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2829665/pdf/nihms82304.pdf>
36. Grover, S. Scoring Systems in Pemphigus. *Indian J Dermatol*. 2011 Mar-Apr; 56(2): 145–149. doi: 10.4103/0019-5154.80403
37. Daniel BS, Hertl M, Weth VP, et al. Severity score indexes for blistering diseases. *Clin Dermatol*. 2012 Jan-Feb; 30(1): 108–113. doi: 10.1016/j.clindermatol.2011.03.017
38. First Coast Service Options, Inc. Local Coverage Determination (LCD): Rituximab (Rituxan®) (L33746). Centers for Medicare & Medicaid Services, Inc. Updated on 9/22/2017 with effective date 10/1/2017. Accessed August 2018.

39. National Government Services, Inc. Local Coverage Article: Rituximab (Rituxan®) (effective 2010) - Related to LCD L33394 (A52452). Centers for Medicare & Medicaid Services, Inc. Updated on 7/6/2018 with effective date of 6/7/2018. Accessed August 2018.
40. Palmetto GBA. Local Coverage Determination: Rituximab (Rituxan®) (L35026). Centers for Medicare & Medicaid Services, Inc. Updated on 05/11/2018 with effective date of 06/13/2018. Accessed August 2018.
41. Wisconsin Physicians Service Insurance Corp. Local Coverage Article: Chemotherapy Agents for Non-Oncologic Conditions (A55639). Centers for Medicare & Medicaid Services, Inc. Updated on 07/17/2018 with effective date 08/01/2018. Accessed August 2018.